Challenges with anti-PD1 agents in brain metastases management of NSCLC patients: a case report
Abstract
Immunotherapy is dramatically changing the therapeutic landscape of advanced Non Small Cell Lung Cancer (NSCLC), with unprecedented results compared with chemotherapy. However, this novel treatment approach poses several novel challenges, including optimal treatment duration, coexistence with other conventional therapies (radiotherapy, targeted therapies, and chemotherapy), and activity in special populations, including patients with brain metastases (BMs). Traditionally, central nervous system (CNS) has been considered an immune-privileged organ, although recent evidences suggest a potential role of the immune system as exploitable target for cancer immunotherapy. Here we present a case of a non-squamous NSCLC patient with a rapid and long-lasting response to the anti-PD1 agent Nivolumab with a remarkable activity in the CNS, without previous brain irradiation.
Keywords
Full Text:
PDFReferences
1. Topalian, S., Hodi, F., Brahmer, J., Gettinger, S., Smith, D., McDermott, D., Powderly, J., Carvajal, R., Sosman, J., Atkins, M., Leming, P., Spigel, D., Antonia, S., Horn, L., Drake, C., Pardoll, D., Chen, L., Sharfman, W., Anders, R., Taube, J., McMiller, T., Xu, H., Korman, A., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G., Gupta, A., Wigginton, J. and Sznol, M. (2012). Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. New England Journal of Medicine, 366(26), pp.2443-2454. doi: 10.1056/NEJMoa1200690.
2. Brahmer, J., Reckamp, K., Baas, P., Crinò, L., Eberhardt, W., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Arén Frontera, O., Havel, L., Steins, M., Garassino, M., Aerts, J., Domine, M., Paz-Ares, L., Reck, M., Baudelet, C., Harbison, C., Lestini, B. and Spigel, D. (2015). Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer. New England Journal of Medicine, 373(2), pp.123-135. doi: 10.1056/NEJMoa1504627.
3. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D., Steins, M., Ready, N., Chow, L., Vokes, E., Felip, E., Holgado, E., Barlesi, F., Kohlhäufl, M., Arrieta, O., Burgio, M., Fayette, J., Lena, H., Poddubskaya, E., Gerber, D., Gettinger, S., Rudin, C., Rizvi, N., Crinò, L., Blumenschein, G., Antonia, S., Dorange, C., Harbison, C., Graf Finckenstein, F. and Brahmer, J. (2015). Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. New England Journal of Medicine, 373(17), pp.1627-1639. doi: 10.1056/NEJMoa1507643.
4. Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S., Hida, T., Kowalski, D., Dols, M., Cortinovis, D., Leach, J., Polikoff, J., Barrios, C., Kabbinavar, F., Frontera, O., De Marinis, F., Turna, H., Lee, J., Ballinger, M., Kowanetz, M., He, P., Chen, D., Sandler, A. and Gandara, D. (2017). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The Lancet, 389(10066), pp.255-265. doi: 10.1016/S0140-6736(16)32517-X.
5. Herbst, R., Baas, P., Kim, D., Felip, E., Pérez-Gracia, J., Han, J., Molina, J., Kim, J., Arvis, C., Ahn, M., Majem, M., Fidler, M., de Castro, G., Garrido, M., Lubiniecki, G., Shentu, Y., Im, E., Dolled-Filhart, M. and Garon, E. (2016). Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet, 387(10027), pp.1540-1550. doi: 10.1016/S0140-6736(15)01281-7.
6. Reck, M., Rodríguez-Abreu, D., Robinson, A., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O’Brien, M., Rao, S., Hotta, K., Leiby, M., Lubiniecki, G., Shentu, Y., Rangwala, R. and Brahmer, J. (2016). Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine, 375(19), pp.1823-1833. doi: 10.1056/NEJMoa1606774.
Ribas, A., Hersey, P., Middleton, M., Gogas, H., Flaherty, K., Sondak, V. and Kirkwood, J. (2011). New Challenges in Endpoints for Drug Development in Advanced Melanoma. Clinical Cancer Research, 18(2), pp.336-341. doi: 10.1158/1078-0432.CCR-11-2323.
7. Brahmer, J., Horn, L., Jackman, D., Spigel, D., Antonia, S., Hellmann, M., Powderly, J., Heist, R., Sequist, L., Smith, D., Leming, P., Geese, W., Yoon, D., Li, A. and Gettinger, S. (2017). Abstract CT077: Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors. Cancer Research, 77(13 Supplement), pp.CT077-CT077. doi: 10.1158/1538-7445.AM2017-CT077.
8. Vokes, E., Ready, N., Felip, E., Horn, L., Burgio, M., Antonia, S., Arén Frontera, O., Gettinger, S., Holgado, E., Spigel, D., Waterhouse, D., Domine, M., Garassino, M., Chow, L., Blumenschein Jr, G., Barlesi, F., Coudert, B., Gainor, J., Arrieta, O., Brahmer, J., Butts, C., Steins, M., Geese, W., Li, A., Healey, D. and Crinò, L. (2018). Nivolumab versus docetaxel in previously treated advanced non-small cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Annals of Oncology. doi: 10.1093/annonc/mdy041.
9. Adamo, V., Franchina, T., Adamo, B., Scandurra, G. and Scimone, A. (2006). Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. Annals of Oncology, 17(suppl_2), pp.ii73-ii75. doi: 10.1093/annonc/mdj930.
10. Zimmermann, S., Dziadziuszko, R. and Peters, S. (2014). Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Cancer Treatment Reviews, 40(6), pp.716-722. doi: 10.1016/j.ctrv.2014.03.005.
11. Russo, A., Franchina, T., Ricciardi, G., Ferraro, G., Scimone, A., Bronte, G., Russo, A., Rolfo, C. and Adamo, V. (2016). Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance. Expert Review of Anticancer Therapy, 16(6), pp.615-623. doi: 10.1080/14737140.2016.1182427.
12. Spigel, D., McLeod, M., Hussein, M., Waterhouse, D., Einhorn, L., Horn, L., Creelan, B., Babu, S., Leighl, N., Couture, F., Chandler, J., Goss, G., Keogh, G., Garon, E., Blankstein, K., Daniel, D., Mohamed, M., Li, A., Aanur, N. and Jotte, R. (2017). 1297O Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC). Annals of Oncology, 28(suppl_5). doi: 10.1093/annonc/mdx380.002.
13. Nishijima, T., Shachar, S., Nyrop, K., Muss, H., 2017. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis. The Oncologist 22, 470-479. doi: 10.1634/theoncologist.2016-0419.
14. Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., Lanoy, E., Texier, M., Libenciuc, C., Eggermont, A., Soria, J., Mateus, C., Robert, C., 2016. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature Reviews Clinical Oncology 13, 473-486. doi: 10.1038/nrclinonc.2016.58.
15. Louveau, A., Smirnov, I., Keyes, T., Eccles, J., Rouhani, S., Peske, J., Derecki, N., Castle, D., Mandell, J., Lee, K., Harris, T. and Kipnis, J. (2015). Structural and functional features of central nervous system lymphatic vessels. Nature, 523(7560), pp.337-341. doi: 10.1038/nature14432.
16. Berghoff, A., Fuchs, E., Ricken, G., Mlecnik, B., Bindea, G., Spanberger, T., Hackl, M., Widhalm, G., Dieckmann, K., Prayer, D., Bilocq, A., Heinzl, H., Zielinski, C., Bartsch, R., Birner, P., Galon, J. and Preusser, M. (2015). Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. OncoImmunology, 5(1), p.e1057388. doi: 10.1080/2162402X.2015.1057388.
17. Remon, J., Vilariño, N. and Reguart, N. (2018). Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions. Cancer Treatment Reviews, 64, pp.21-29. DOI: 10.1016/j.ctrv.2018.02.002.
18. Goldberg, S., Gettinger, S., Mahajan, A., Chiang, A., Herbst, R., Sznol, M., Tsiouris, A., Cohen, J., Vortmeyer, A., Jilaveanu, L., Yu, J., Hegde, U., Speaker, S., Madura, M., Ralabate, A., Rivera, A., Rowen, E., Gerrish, H., Yao, X., Chiang, V. and Kluger, H. (2016). Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. The Lancet Oncology, 17(7), pp.976-983. doi: 10.1016/S1470-2045(16)30053-5.
19. Dudnik, E., Yust-Katz, S., Nechushtan, H., Goldstein, D., Zer, A., Flex, D., Siegal, T. and Peled, N. (2016). Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. Lung Cancer, 98, pp.114-117. doi: 10.1016/j.lungcan.2016.05.031.
20. Goldman, J., Crino, L., Vokes, E., Holgado, E., Reckamp, K., Pluzanski, A., Spigel, D., Kohlhaeufl, M., Garassino, M., Chow, L., Gettinger, S., Gerber, D., Havel, L., Ramalingam, S., Dy, G., Geese, W., Li, A., Blackwood-Chirchir, A., Healey, D., Brahmer, J. and Lopes, G. (2016). P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets). Journal of Thoracic Oncology, 11(10), pp.S238-S239. doi: 10.1016/j.jtho.2016.08.107.
21. Ahmed, K., Kim, S., Arrington, J., Naghavi, A., Dilling, T., Creelan, B., Antonia, S., Caudell, J., Harrison, L., Sahebjam, S., Gray, J., Etame, A., Johnstone, P., Yu, M. and Perez, B. (2017). Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. Journal of Neuro-Oncology, 133(2), pp.331-338. doi: 10.1007/s11060-017-2437-5.
22. Crinò, L., Bidoli, P., Ulivi, P., Minenza, E., Cortesi, E., Garassino, M., Cappuzzo, F., Grossi, F., Tonini, G., Sarobba, M., Pinotti, G., Numico, G., Samaritani, R., Ciuffreda, L., Frassoldati, A., Bregni, M., Santo, A., Piantedosi, F., Illiano, A., De Marinis, F. and Delmonte, A. (2017). P1.01-053 Italian Nivolumab Expanded Access Programme (EAP): Data from Patients with Advanced Non-Squamous NSCLC and Brain Metastases. Journal of Thoracic Oncology, 12(11), p.S1915. doi: 10.1016/j.jtho.2017.09.707.
23. Molinier, O., Audigier-Valette, C., Cadranel, J., Monnet, I., Hureaux, J., Hilgers, W., Fauchon, E., Fabre, E., Besse, B., Brun, P., Coëtmeur, D., Quoix, E., Mourlanette, P., Barlesi, F., Bordenave-Caffre, S., Egenod, T., Missy, P., Morin, F., Moro-Sibilot, D. and Girard, N. (2017). OA 17.05 IFCT-1502 CLINIVO: Real-Life Experience with Nivolumab in 600 Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 12(11), p.S1793. doi:10.1016/j.jtho.2017.09.430.
24. Gauvain, C., Vauléon, E., Chouaid, C., Lerhun, E., Jabot, L., Scherpereel, A., Vinas, F., Cortot, A., Monnet, I., 2018. Intracerebral efficacy and tolerance of nivolumab in non–small-cell lung cancer patients with brain metastases. Lung Cancer 116, 62-66. doi: 10.1016/j.lungcan.2017.12.008.
25. Pike, L., Bang, A., Ott, P., Balboni, T., Taylor, A., Catalano, P., Rawal, B., Spektor, A., Krishnan, M., Cagney, D., Alexander, B., Aizer, A., Buchbinder, E., Awad, M., Gandhi, L., Hodi, F. and Schoenfeld, J. (2017). Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiotherapy and Oncology, 124(1), pp.98-103. doi: 10.1016/j.radonc.2017.06.006.
26. Stokes, W., Binder, D., Jones, B., Oweida, A., Liu, A., Rusthoven, C. and Karam, S. (2017). Impact of immunotherapy among patients with melanoma brain metastases managed with radiotherapy. Journal of Neuroimmunology, 313, pp.118-122. doi: 10.1016/j.jneuroim.2017.10.006.
27. van Vulpen, M., Kal, H., Taphoorn, M. and El Sharouni, S. (2002). Changes in blood-brain barrier permeability induced by radiotherapy: Implications for timing of chemotherapy? (Review). Oncology Reports. doi: 10.3892/or.9.4.683.
28. Takamori, S., Toyokawa, G., Takada, K., Shoji, F., Okamoto, T. and Maehara, Y. (2018). Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non–Small-cell Lung Cancer: A Mini-review. Clinical Lung Cancer, 19(1), pp.12-16. doi: 10.1016/j.cllc.2017.06.015
29. Hubbeling, H., Schapira, E., Horick, N., Goodwin, K., Lin, J., Oh, K., Shaw, A., Mehan, W., Shih, H., Gainor, J., 2018. Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. doi: 10.1016/j.jtho.2018.01.012.
30. Colaco, R., Martin, P., Kluger, H., Yu, J. and Chiang, V. (2016). Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?. Journal of Neurosurgery, 125(1), pp.17-23. doi: 10.3171/2015.6.JNS142763.
31. Alomari, A., Cohen, J., Vortmeyer, A., Chiang, A., Gettinger, S., Goldberg, S., Kluger, H. and Chiang, V. (2016). Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases. Cancer Immunology Research, 4(6), pp.481-487. doi: 10.1158/2326-6066.CIR-15-0238
32. Hanahan, D. and Weinberg, R. (2011). Hallmarks of Cancer: The Next Generation. Cell, 144(5), pp.646-674. doi: 10.1016/j.cell.2011.02.013.
33. Blank, C., Haanen, J., Ribas, A. and Schumacher, T. (2016). The "cancer immunogram." Science, 352(6286), pp.658-660. doi: 10.1126/science.aaf2834.
34. Scharping, N., Menk, A., Whetstone, R., Zeng, X. and Delgoffe, G. (2016). Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia. Cancer Immunology Research, 5(1), pp.9-16. doi: 10.1158/2326-6066.CIR-16-0103.
DOI: https://doi.org/10.6092/1828-6550/APMB.106.1.2018.A6
Refbacks
- There are currently no refbacks.
Copyright (c) 2018 Alessandro Russo, Tindara Franchina, Giuseppina Rosaria Rita Ricciardi, Alessandra Battaglia, Antonino Scimone, Vincenzo Adamo
This work is licensed under a Creative Commons Attribution 4.0 International License.